First National Advisers LLC Has $2.50 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

First National Advisers LLC grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 27,914 shares of the medical equipment provider’s stock after purchasing an additional 1,098 shares during the period. First National Advisers LLC’s holdings in Lantheus were worth $2,497,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D increased its holdings in Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after purchasing an additional 115 shares during the period. Bleakley Financial Group LLC boosted its position in shares of Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock worth $200,000 after purchasing an additional 129 shares in the last quarter. Avantax Advisory Services Inc. lifted its position in Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after acquiring an additional 132 shares in the last quarter. UMB Bank n.a. lifted its position in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares in the last quarter. Finally, Aurora Investment Counsel lifted its position in Lantheus by 0.8% in the 4th quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider’s stock valued at $1,718,000 after acquiring an additional 146 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

NASDAQ LNTH opened at $101.10 on Friday. The company has a market capitalization of $6.92 billion, a PE ratio of 16.82 and a beta of 0.38. The company has a fifty day moving average of $92.07 and a 200 day moving average of $96.77. Lantheus Holdings, Inc. has a 1 year low of $56.44 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. JMP Securities reiterated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.